Trial Profile
A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group and Phase III Clinical Trial to Evaluate in Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Cilostazol/ginkgo biloba (Primary)
- Indications Peripheral arterial occlusive disorders
- Focus Therapeutic Use
- Sponsors SK Chemicals
- 08 Apr 2022 Primary endpoint (Variation in lower limb pain (VAS)) has been met, according to Results published in the Clinical Therapeutics .
- 08 Apr 2022 Results published in the Clinical Therapeutics
- 18 Sep 2019 Status changed from active, no longer recruiting to completed.